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Background: Integrative medicine (IM) is a patient-centered, healing-oriented clinical paradigm that explicitly
includes all appropriate therapeutic approaches whether they originate in conventional or complementary medicine
(CM). While there is some evidence for the clinical and cost-effectiveness of IM practice models, the existing evidence
base for IM depends largely on studies of individual CM therapies. This may in part be due to the methodological
challenges inherent in evaluating a complex intervention (i.e., many interacting components applied flexibly and
with tailoring) such as IM.
Methods/Design: This study will use a combination of observational quantitative and qualitative methods to
rigorously measure the health and healthcare utilization outcomes of the University of Arizona Integrative Health
Center (UAIHC), an IM adult primary care clinic in Phoenix, Arizona. There are four groups of study participants. The
primary group consists of clinic patients for whom clinical and cost outcomes will be tracked indicating the impact
of the UAIHC clinic (n = 500). In addition to comparing outcomes pre/post clinic enrollment, where possible, these
outcomes will be compared to those of two matched control groups, and for some self-report measures, to regional
and national data. The second and third study groups consist of clinic patients (n = 180) and clinic personnel
(n = 15-20) from whom fidelity data (i.e., data indicating the extent to which the IM practice model was implemented
as planned) will be collected. These data will be analyzed to determine the exact nature of the intervention as
implemented and to provide covariates to the outcomes analyses as the clinic evolves. The fourth group is made up of
patients (n = 8) whose path through the clinic will be studied in detail using qualitative (periodic semi-structured interviews)
methods. These data will be used to develop hypotheses regarding how the clinic works.
Discussion: The US health care system needs new models of care that are more patient-centered and empower
patients to make positive lifestyle changes. These models have the potential to reduce the burden of chronic
disease, lower the cost of healthcare, and offer a sustainable financial paradigm for our nation. This protocol has
been designed to test whether the UAIHC can achieve this potential.
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This article describes the protocol for a two-year study
of the health and economic impact of a primary care in-
tegrative medicine (IM) clinic. IM is defined as a health
promoting, prevention-oriented clinical paradigm that
explicitly includes conventional medical treatment to-
gether with the use of complementary medicine (CM)
modalities that have sufficient evidence and safety for
use [1-5]. Practice models in IM are emerging [6], but
most of the models provide consultative or specialty
care; few provide primary care. There are also few meth-
odologically valid health services research studies on the
clinical and cost effectiveness of IM practice models,
particularly for primary care [7-12].
The evaluation of a IM primary care model presents a
number of methodological challenges. Some are the re-
sult of the evolving nature of the concept of IM [12],
and most have been discussed in the literature to illus-
trate the complex needs of CM research [13-20]. In gen-
eral, these challenges apply to research involving any
complex intervention (e.g., a new care delivery model)
[21-24]. Each challenge is discussed below accompanied
by recommended solutions.
Complex, individualized intervention
Although IM is defined as both a clinical treatment
paradigm and a practice organization model, the existing
evidence base for IM depends largely on studies of the in-
dividual components [7,8,10,14,25]. While IM combines
conventional and evidence-based CM modalities (having
practitioners who can offer these CM modalities is an im-
portant aspect of the practice organization model), it is
also a larger clinical paradigm for a process of whole per-
son, patient-centered, healthcare that embraces the innate
healing capacity of the human organism and attends to
the importance of lifestyle [2,26,27]. Whether seen as a
clinical paradigm or as a practice model, IM meets the
definition of a complex intervention. It consists of a num-
ber of interacting components that make up and affect
care, and these components are applied with a large de-
gree of flexibility and tailoring [28]. To create an evidence
base for IM itself, studies that characterize and evaluate
the outcome of intact IM clinic practices are needed.
Several researchers have recommended that complex in-
terventions simply be studied as "black boxes” [14,16,19,20];
as interventions whose outputs can be measured, but
whose internal mechanisms are unknown. Since subjects
can be randomized to one black box or another, no new
methods are required. Others recommend that the boxes
be "unpacked”—that every element in the intervention be
defined and its outcomes measured [29,30]. The "black
box" approach offers no assurance that the box contents
are a valid representation of the intervention; however,
given the number of different treatments and potentialdiagnoses, complete "unpacking" may prove an insur-
mountable measurement, analysis, and interpretation
challenge. The concept of implementation fidelity offers
a balance between these two extremes. Outcomes are
still measured for, and attributed to, the intervention as
a whole (the “box”). However, the contents of the box
are defined and measured to document what was actu-
ally delivered—i.e., what the box contains.
When a study compares two drugs (or a drug to pla-
cebo), all else is held (or assumed to be) equal – in part
through randomization, and in part through strict study
protocols, including participant and practitioner blind-
ing. As both comparison groups are being treated within
the same practice model (e.g., conventional primary
care), little, if any, effort is given to defining that model.
Faithfulness to the intended intervention, defined as
Intervention implementation fidelity, is ensured through
monitoring adherence to protocols. The objective is to
ensure that the only difference between groups is receipt
of the drug under study [22].
In contrast, when two practice models are compared
in a study, very little can be held equal. The study proto-
col is by necessity less prescriptive as to what is deliv-
ered, when, how, and by whom. The constraints placed
upon possible interventions are loosened to allow practi-
tioner autonomy in individualizing patient care. Not only
may different treatments be offered, but different practi-
tioners with different training may diagnose and then
prescribe those treatments with different clinical goals
and under different philosophies of care. Some method
of defining the practice models is needed to capture and
measure differences to ensure that interventions are im-
plemented as intended, and to know what is actually be-
ing compared.
The concept of intervention implementation fidelity
emerged in the 1960s in the field of psychotherapy when
early attempts to sort out design and interpretive problems
in outcomes studies proved impossible. For an overview
of fidelity and its measurement, see Bond et al. [31]. Since
the 1960s, including measures of intervention fidelity has
become a standard requirement for research in a number
of applied fields, including medicine [21,22,24,28,32,33].
Fidelity monitoring is important for the interpret-
ation of study results (e.g., avoidance of Type III
error – erroneously concluding that an intervention had
no impact when it was actually not implemented), and for
replication [22,23,32]. Fidelity measures can also be used
as covariates in the analyses to determine treatment effect
and avoid invalid statistical conclusions [24].
Assessment of implementation fidelity will help with
defining ‘what was measured’ in complex interventions.
However, to understand the ‘why it happened’ causal ef-
fects of IM, a number of researchers have recommended
the use of mixed methods—e.g., including qualitative
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controlled trials (RCTs), even when coupled with advanced
quantitative methods, cannot explain complex causal re-
lationships [20,21]. Well-designed multi-method studies
allow a deeper understanding of the mechanisms that
might be at work in the intervention [21].
Whole person outcomes as markers of effectiveness
IM’s focus on treating the whole person, is believed to
have outcomes beyond those associated with treatment
of the targeted condition [25,35]. The emphasis on self-
care, the benefits of a good patient-practitioner relation-
ship, and the promotion of the body’s self-healing capacity
are all believed to result in enhanced health [35]. In par-
allel to the concept of treating the whole person is the
concept of using a whole system of healthcare services
delivery. In IM this includes a focus on the patient-
provider relationship and a full range of potential treat-
ments. Together these result in the need to measure
outcomes across a number of dimensions (e.g., spiritual,
social, physical, mental, emotional) [29,36]. The Federal
Coordinating Council for Comparative Effectiveness
Research (CER) has stressed the importance of “assessing
a comprehensive array of health-related outcomes…” [37]
to provide the information that patients, clinicians and
policy makers need to make good healthcare decisions.
Patient preferences and the infeasibility of randomization
Patients are rarely neutral about IM. They typically in-
dicate strong preferences for or against this approach to
healthcare, which makes it hard to accrue patients in
randomized trials [14]. In the absence of the ability to
randomize appropriately, observational approaches are
recommended [16,18]. Observational studies are also
recommended for complex systems [19] and to capture
actual practice [29]. When well-designed, they have
been found to produce results comparable to RCTs,
neither over- nor underestimating treatment effects
[38-40]. CER methods allow for studies of all types of
health-related interventions, including delivery systems
[21], and recognize observational studies as valid de-
signs [41-43].
The protocol described in this article addresses the
clinical and economic evaluation of an IM primary care
clinic. Although the outcomes and processes of care of
this particular clinic, as defined in its business plan, are
being evaluated, it is anticipated the findings from this
study will contribute to IM health services research in
general. Because IM practice is a complex intervention,
the study design includes fidelity monitoring and evalu-
ation, and an observational design that includes qualitative
data collection and analysis. And because IM practice
offers whole-person care, a broad range of outcomes are
being measured.Methods/Design
This two-year study is Phase II of a two-phase, three-
year project. The purpose of Phase I was to design the
protocol for the Phase II study, including clarifying the
design of the IM clinic model to be tested and identifying
the measures to use for outcomes and to monitor treat-
ment fidelity. The purpose of Phase II is to conduct a
prospective outcomes evaluation of the clinical and cost
effectiveness of an IM professional practice model for
adult primary care.
Study design
A combination of observational quantitative and qualita-
tive study designs will be used to measure the health
and healthcare utilization outcomes of a primary care
IM clinical model. Where possible, the clinical and eco-
nomic impacts seen in this IM model will be compared
to data available from one or more comparison groups
(see discussion of comparison groups below). When
comparison group data are not available for outcomes —
e.g., for most of the self-report data and for the medical
records data—baseline values for clinic participants will
be compared to those measured during and after treat-
ment. Table 1 shows the types of comparisons planned
for each outcome data category for the observational
study.
Because the IM professional practice model is a com-
plex intervention, implementation fidelity will be assessed,
in addition to clinical and economic outcomes. Fidelity
data (gathered on patients’ and practitioners’ experiences
and from medical record data) will serve four purposes.
First, these data will be used as a measure of intervention
integrity—i.e., was the intervention/practice delivered as
intended. Second, because integrative primary care has
not previously been defined and evaluated, and since the
clinic under study is new, and thus continuously develop-
ing and modifying operational and treatment protocols
and procedures, these fidelity data will also describe what
happened. Third, data on operations and how they may
have evolved over time are important as potential covari-
ates in the analysis of outcomes, for proper interpretation
of results, and for external validity and replication. Finally,
fidelity data provide quality control feedback to clinic staff
as to how the IM clinic model is being implemented by
staff and perceived by patients. This will allow for quality
improvements of the IM primary care clinic over time.
This study received the approval of the University of
Arizona Institutional Review Board, and is registered in
clinicaltrials.gov (NCT01785485).
Setting and Participants
Data used in the evaluation will be gathered from eli-
gible and consenting participants who are also patients
enrolled at the University of Arizona Integrative Health
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2.0 data [50].
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care clinic in Phoenix, Arizona. Operated in conjunction
with District Medical Group, Inc., UAIHC is financed
through insurance reimbursements and a patient mem-
bership fee structure. At present, two major employers
in the Phoenix area pay a portion of the membership fee
for their employees who elect UAIHC as their primary
care provider. There are four groups of study partici-
pants. The first (and main) group consists of eligible par-
ticipants from the clinic patient population for whom
clinical and cost outcomes will be tracked indicating the
impact of the UAIHC clinic (n = 500). The second and
third groups consist of clinic patients (n = 180) and clinic
personnel (n = 15-20) from whom fidelity data will be
collected. The fourth group is made up of the patients(n = 8) whose path through the clinic will be studied in
detail using qualitative methods. The clinic patients in-
volved in the outcomes study sample may or may not be
included in the fidelity patient sample, and vice versa.
However, the qualitative data sample is expected to be a
subset of the outcomes sample.Outcomes sample
Only patients who are members at UAIHC and who
meet the inclusion/exclusion criteria are eligible to en-
roll in this study. Participation in the study will continue
for at least one year after enrollment. It is anticipated
that at least 500 patients will consent to participation
during the first nine months of the study. Our primary
outcome for our main analysis is change in total costs
(see the Analysis section below). Using the standard de-
viation seen in a set of healthcare utilization data from a
related group, a sample size of 200 patients should be
sufficient to detect a small effect size (Cohen’s d = .20)
difference in total costs at a .80 power using an alpha
of .05. Therefore, our expected sample size of 500 may
also allow for some subgroup analysis. Inclusion criteria:
1) Enrollment in primary care (members) at UAIHC; and,
2) adults ages 18 or older. Exclusion criteria: 1) currently
pregnant at time of recruitment; 2) patients who attend
the UAIHC clinic as “consultation-only” patients; and,
3) significant cognitive impairment to the extent that
the individual is unable to understand the consent and
respond to questionnaires.
All new patients will be advised by their primary care
physician that they may be eligible to participate in a
study to evaluate the effectiveness of the UAHIC. Prior
to checkout, patients have an exit session with the
University of Arizona (UA) Study Coordinator. During
this session (or if necessary, through a follow-up phone
call), the Study Coordinator will explain the nature of
the study and make a determination of study eligibility,
and if appropriate, consent the patient. Patients who joined
the UAIHC before study start (July 2013) will also have
the opportunity to participate. The study will be explained
at their first UAIHC visit after study start.Fidelity patient sample
Participants in the fidelity study will include both UAIHC
patients and members of the UAIHC clinic team. On fi-
delity assessment sample days (a single randomly chosen
day of the last week of the data collection month; see data
collection procedures below), participants will be recruited
and enrolled from all patients who enter the UAIHC wait-
ing room. It is anticipated that approximately 180 patients
will consent to participation across the two-year study
period. The inclusion/exclusion criteria for this sample are
identical to those used for the outcomes sample with the
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allowed to participate in this sample.
At check in on the fidelity data collection day, front
desk staff will make a printed handout available describ-
ing a “How is UAIHC Doing?” evaluation, and asking all
patients seen that day to provide feedback through an
online questionnaire after that day’s visit. Interested pa-
tients will supply their e-mail address and check a box
on the printed handout expressing permission to receive
the online questionnaire. The UA Study Coordinator will
send all interested patients an e-mail with instructions
and a link to the secure URL address for the fidelity in-
formed consent form and the Web-based questionnaire.
Patients preferring to complete the questionnaire on paper
will have the opportunity to receive a hard copy from the
front desk (or by mail) with instructions to place com-
pleted questionnaires in a secure box at the clinic (or to
return them using the enclosed self-addressed stamped
envelope). Digitally-signing the informed consent form,
or returning a signed paper-based consent form will
constitute completion of the informed consent process
for fidelity. Patients who complete the questionnaire within
10 days will receive a $10 gift card.
Fidelity clinic personnel sample
The UA Study Coordinator will enroll UAIHC personnel
at study start by sending an e-mail with a link to the se-
cure URL address and password information for the in-
formed consent form. Assessments will be on the same
schedule as for patient fidelity (see Data collection below).
A total of 15–20 clinic personnel (the entire UAIHC staff)
will be enrolled in the fidelity study. The same consent
process and incentive will be used as for the fidelity pa-
tient sample.
Qualitative/case study sample
The qualitative study sample will be a subset of the out-
comes sample. In addition to the inclusion and exclusion
criteria of the outcomes sample subjects will consist of
members who joined the study during its first three
months. The qualitative study will be introduced to pa-
tients by the UA Study Coordinator during the same
meeting in which the outcomes study is discussed. Par-
ticipation will require an additional consent, and will en-
tail a 20–30 minute semi-structured, taped interview
immediately following each regular outcome data collec-
tion points.
Intervention
The IM professional practice model for primary care
utilizes an inter-professional, physician-led, integrative
clinical team to provide patient-centered care. UAIHC
services include conventional medical care, lifestyle in-
terventions, and evidence-based CM interventions. Inparticular, services include longer visits with providers,
a commitment to health, a partnership agreement with
the health care team, increased access via telephone and
email in addition to in-person visits and classes, and a
wider range of services including nutritional counseling,
acupuncture, chiropractic care, stress-reducing mind-body
approaches, and health coaching. In addition to individual
appointments, group visits and health promotion classes
are offered (e.g., nutrition, yoga, meditation). Emphasis is
placed on motivating and supporting lifestyle behavior
change. Although patients with a wide variety of diagnoses
will be eligible and included in the study, outcomes for pa-
tients with the following five conditions (low back pain,
fibromyalgia, other musculoskeletal conditions, metabolic
syndrome and diabetes, and cardiovascular disease) will
be analyzed separately where possible.
The UAIHC business model uses a hybrid financing
approach that utilizes usual insurance reimbursements
supplemented by a patient membership fee. The mem-
bership fee covers a certain number of CM practitioner
visits, health coaching visits, and classes (a “class” may
comprise a series of individual sessions). Three fee tiers
have been established: 1) basic bundle (5 visits with the
patient’s choice of CM practitioners, 2 visits with a
health coach, and 2 groups or classes); 2) core (10 visits
with the CM practitioners of choice, 4 health coach
visits, and 4 groups or classes); and, 3) expanded (20
visits with CM practitioners, 8 visits with a health coach,
and 8 groups or classes). For some members, this fee is
partially offset by collaborating employers who offer
UAIHC as an employee health benefit option. (Grant
funding supports the costs of this study for those partici-
pants employed with these collaborators).
According to its business plan, the IM primary care
practice model will follow IM principles [44] as well as the
principles of primary care [45,46] and the patient-centered
medical home [47]. More detail on the IM primary care
practice model is presented in Dodds et al [48].
Comparison group(s)
Data from UAIHC patients will be compared, where
possible, to those of patients seen in other clinics. The
primary outcome, total healthcare utilization, will be
obtained from healthcare claims data for patients whose
employers have given access to those data. For these pa-
tients, matched comparison groups will be developed
using two different matching algorithms applied to de-
identified claims data for non-UAIHC patients. One will
use a straight matching algorithm based on age and gen-
der, and the other will use propensity scores to match
[49]. At least one of the participating employers also has
employee lab values available. Where these data are
available, the same matched comparison groups will be
used to compare changes in key lab values seen across
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national and regional comparisons available. The mea-
sures of patient experiences and patient satisfaction are
drawn from the Consumer Assessment of Healthcare
Providers and Systems (CAHPS) Adult Visit Survey 2.0
[50]. The CAHPS website contains data on the results
of these questions nationally, by region, and by phys-
ician specialty. The results seen for UAIHC participants
will be compared to those seen by all providers nation-
ally, by all providers in the West region, and by family
practice doctors nationally. The measures of diet and
exercise quality come from the Center for Disease Control
and Prevention’s Behavioral Risk Factor Surveillance
System survey [51]. National and statewide averages are
available for these items. Unfortunately, no other second-
ary data sources are available for comparisons. For all
other outcomes, UAIHC participants will act as their own
controls by comparing their outcome measures over time
to baseline.
Data Collection
For the outcomes evaluation, data will be collected from
patient charts and self-reports at four intervals—baseline
(initial clinic visit), and at 3-, 6-, and 12-month follow
up periods. Participants will receive a reminder email
one week before each data collection due date. Baseline
data will be due within one week of enrollment. In the
email they will be directed to a secure website where
they can access and complete the outcomes data collec-
tion instrument. If participants have not entered their
data within 3 days of their due date, they will receive an-
other reminder email, and those who have not entered
their data within another 3 days of their due date will re-
ceive a call from the UA Study Coordinator. Healthcare
utilization and cost data from healthcare claims will be
obtained from their employer with study participant
consent. These data will be collected for one year before
and one year after clinic enrollment approximately
3 months after the 12-month follow up period to allow
time for all incurred claims to be recorded. De-identified
claims data for the comparison groups will be collected
for the same period of time with “baseline” being defined
by the average start date of study participants.
Because the intervention may change over time as
clinic operations start up and mature [21], fidelity moni-
toring data will be collected monthly from study start
for 6 months, then quarterly for 6 months, and then
semi-annually. Patient-reported fidelity data will be gath-
ered on a single randomly chosen day of the last week of
the data collection month from all patients seen at the
UAIHC clinic that day. This day will be selected by the
UA research team using a simple computer generated
randomization scheme and delivered to the UA Study
Coordinator the week before the data collection week. Aself-administered patient version of the “How is UAIHC
doing?” questionnaire will be used for patients. For clinic
personnel, fidelity data will be collected during the last
week of each fidelity data collection month using an on-
line self-administered practitioner and staff version of
the “How is UAIHC doing?” questionnaire. Data from
audits of randomly selected, de-identified patient charts
and of administrative records will also be used to assess
indicators of model implementation.
Qualitative data in the form of the results of 20–30 minute
semi-structured interviews will be collected by phone or
in-person approximately every three months, and at other
significant points in time if the patient agrees—e.g., if the
patient chooses to leave the clinic or there is a dramatic
change in the patient’s use of clinic services. The focus is
to collect real-time data on what the patient believes is
the cause of any changes (or lack of change) seen in
their health.
Outcome measures
Data on clinical and economic outcomes will be col-
lected from three main sources: self-report instruments,
chart abstraction, and health plan administrative data
(healthcare utilization and, where available, lab values)
from participants’ employers. Because integrative medi-
cine approaches treat the whole person, rather than sim-
ply targeting a specific disease or symptom, they can
have broad impacts on health [25,29,35,36]. Therefore, a
broad set of clinical and economic outcomes for the
UAIHC will be captured (Table 1). These are each dis-
cussed below, starting with the self-report measures. All
are collected at baseline (some directly and some as part
of patients’ initial clinic intake form), and then 3, 6 and
12 months and semi-annually thereafter, unless other-
wise noted.
Self-report instruments – all patients
In addition to general socio-demographic data and an
item on patients’ expectations of the clinic (both asked
only at baseline), several factors are captured that could
be seen as overall determinants of health and/or inter-
mediate outcomes: diet, exercise, self-efficacy, stress,
sleep and patient satisfaction. In addition, a number of
specific (pain, fatigue, depression and anxiety) and global
(quality of life, well-being, and work productivity) out-
comes are captured. Each is described briefly below. It is
estimated that it will take patients 15–20 minutes to
complete these instruments.
 Diet quality. Diet quality is assessed by the Fruits
and Vegetables module of the Behavioral Risk Factor
Surveillance System [51]. Six items assess the type of
fruits, vegetables, and legumes eaten in the past
month and their frequency.
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assessed by the Exercise/Physical Activity module of
the Behavioral Risk Factor Surveillance System [51].
Eight items assess the type, frequency, and duration
of exercise/physical activity in the past month.
 Health self-efficacy. The Patient Activation Measure
(PAM) is a 13-item self-assessment of an individual’s
knowledge, skill, willingness, and confidence in
managing their health and health care (activation)
[52,53]. Scores stratify patients into four levels of
health care activation.
 Stress. Several aspects of stress are captured. The
Perceived Stress Scale (PSS) [54] is a brief measure
that assesses the degree to which situations in one’s
life are appraised as stressful in a global manner.
Items tap how unpredictable, uncontrollable, and
overloaded respondents find the stress in their lives
to be. Two single items, found to strongly correlate
with established multi-item measures, are used to
tap the psychological response to stress and the
amount of stress experienced in the past year [55].
 Sleep quality. Sleep quality is assessed by the 9-item
Pittsburgh Sleep Quality Index (PSQI) [56]. The PSQI
measures the quality and patterns of sleep over the
past 1 month. It differentiates “poor” from “good”
sleep by inquiring about seven areas: 1) subjective
sleep quality, 2) sleep latency, 3) sleep duration,
4) habitual sleep efficiency, 5) sleep disturbances,
6) use of sleeping medication, and 7) daytime
dysfunction.
 Patient satisfaction. The 2-item measure of patient
satisfaction is from the Consumer Assessment of
Healthcare Providers and Systems (CAHPS) Survey
2.0 Adult visit version [50,57]. These items are not
included at baseline.
 Pain (global). Global rating of pain is assessed by a
single-item pain visual analogue scale (pVAS) [58]. It
measures severity of pain over the past week.
 Fatigue. Both a global rating and specific symptoms
of fatigue are captured. Global rating of fatigue is
assessed by a single-item fatigue visual analogue
scale (fVAS). It measures the severity of fatigue over
the past week. The 9-item Fatigue Severity Scale
(FSS) [59] assesses how fatigue affects motivation,
exercise, physical functioning, carrying out duties,
and interfering with work, family, or social life in the
past 1 week.
 Depression. The 2-item ultra-brief Patient Health
Questionnaire (PHQ-2) [60] is used to assess core
symptoms of major depression. The items ask how
often over the last 2 weeks participants were bothered
by 1) having little interest or pleasure in doing things
(anhedonia), and 2) feeling down, depressed, or
hopeless (depressed mood). Scores of ≥ 3 have asensitivity of 83 % and a specificity of 92 % for major
depression. Patients with scores of ≥ 3 will also receive
the full PHQ-9 (below).
 Generalized Anxiety Disorder. The 2-item ultra-brief
Generalized Anxiety Disorder questionnaire (GAD-2)
[61] is used to assess core symptoms of anxiety
disorder. The items ask patients how often over
the last 2 weeks they were bothered by 1) feeling
nervous, anxious, or on edge and 2) not being
able to stop or control worrying. Scores of ≥ 3
have a sensitivity of 86 % and a specificity of 83 %
for Generalized Anxiety Disorder. Patients with
scores of ≥ 3 will also receive the full GAD-7
below.
 Health-related Quality of Life. Health-related quality
of life is assessed by the 12-Item Short Form Medical
Outcomes Survey (SF-12) [62]. The SF-12 is a general
measure of health status and well-being that
assesses physical functioning, role limitations due to
physical health, bodily pain, general health, energy/
fatigue, social functioning, and role limitations due
to emotional problems and mental health in the
past 4 weeks.
 Psychological Well-being. Psychological well-being is
assessed by the 5-item World Health Organization
Well-Being Index (WHO-5) [63]. The WHO-5
assesses subjective quality of life as a dimension
separate from social disability and asks about
dimensions such as positive mood, vitality, and
interest in life in the past 2 weeks.
 Health-related work productivity (absenteeism/
presenteeism). Health-related work productivity is
assessed by the 6-item Work Productivity and
Activity Impairment questionnaire (WPAI) [64]. The
WPAI is a self-administered instrument to assess the
impact of disease on absenteeism (work time missed),
presenteeism (reduced on-the-job effectiveness), and
impairment in daily activity.
 Healthcare utilization. Four items based on Ritter
et al. (2001) [65] ask about use of healthcare services
in the prior period—from primary care providers
outside of UAIHC, from specialists, from
emergency rooms or urgent care centers, and
overnight hospital stays.
Self-report instruments – condition specific
For participants diagnosed by UAIHC with any of the
identified study clinical conditions (low back pain,
fibromyalgia, depression and anxiety), one or more of
the following questionnaires will be added:
 Fibromyalgia Impact Questionnaire Revised - FIQR.
The 21-item FIQR is a patient report of symptoms
associated with fibromyalgia in three domains:
Herman et al. BMC Complementary and Alternative Medicine 2014, 14:132 Page 8 of 12
http://www.biomedcentral.com/1472-6882/14/132physical functioning (9 items), overall impact
(2 items), and symptoms (10 items) [66].
 Roland-Morris Disability Questionnaire – RMDQ.
The RMDQ is a patient report of physical disability
due to low back pain (Roland & Morris, 1983). The
RMDQ contains 24 yes/no items focused on
limitations in walking, bending over, sitting, lying
down, dressing, sleeping, self-care, and daily
activities.
 Patient Health Questionnaire 9 - PHQ-9. To assess
clinical depression, the PHQ-9 [67,68] will be used
with patients if the PHQ-2 screening score is ≥ 3.
 Generalized Anxiety Disorder 7 - GAD-7. When
scores on the GAD-2 exceed the cut point of ≥ 3 on
the New Patient Intake Form, the 7-item GAD-7
will be administered [69].Data collected from medical records
These data will be collected at 3, 6, and 12 months. A
medical records abstraction form will be used to collect
the following from the patient chart for the period since
the last outcomes data collection point. The results of
any of the following lab tests will be captured: fasting
glucose, lipid panel, thyroid stimulating hormone (TSH),
glycosylated hemoglobin (HbA1c), inflammatory markers
(erythrocyte sedimentation rate and high-sensitivity
C-reactive protein), vitamin D status, and measures of
anemia (hemoglobin, hematocrit, and mean corpuscular
volume). Also captured will be each patient’s diagnosis
(es), systolic and diastolic blood pressure, heart and re-
spiratory rates, weight, waist circumference, body fat
composition, smoking status, and whether the patient is
on hypoglycemic, dyslipidemia, or hypertension medica-
tion. Composite scores (10-year cardiovascular disease
(CVD) event risk [70], 10-year CVD mortality risk [71],
and metabolic syndrome diagnosis [72]) will be captured
from the chart when recorded, or will be calculated. Forced
vital capacity and forced expiratory volume will be captured
for participants with pulmonary disease.Health Insurance Claims Data
Annually, the UA Study Coordinator will create a coded,
numeric list of study participants, who are employees or
adult dependents of participating employer groups, to
send to their health plan. This list will enable the health
plan to generate and return a file of otherwise de-
identified health claims data. Study participants will be
identifiable (a partial waiver of protected health informa-
tion data was granted by the UA Institutional Review
Board) so that healthcare utilization data can be matched
to their other study data, and the remainder of the file will
be used to generate the matched control groups. The ini-
tial data request will cover one year prior and one yearafter clinic enrollment for study participants, and a com-
parable 2-year period for non-participants.
Fidelity monitoring measures
Patient feedback questionnaire
Patient experiences of the various dimensions of integra-
tive medical care will be assessed for their same-day care
by a 51-item “How is UAIHC doing?” Patient Version
questionnaire developed for the fidelity study. Dimensions
of the questionnaire include access to care, whole person
care, promotion of self-care and wellness, practitioner
communication style, shared decision-making, trust in the
practitioner, perceived practitioner empathy, perceived
health partnership, and socio-demographic information.
Items were derived from established measures of primary
care quality: the Consumer Assessment of Healthcare
Providers and Systems (CAHPS) Surveys 2.0 Adult
visit and Patient-Centered Medical Home versions [50,57],
the Ambulatory Care Experiences Survey (ACES) [73], and
the Consultation and Relational Empathy measure (CARE)
[74]. Several items were developed for the study to tap
patient experiences of IM care not assessed in existing
instruments. It is estimated that it will take 10–15 minutes
for patients to complete this questionnaire.
Patient chart extraction
A number of items will be extracted from a random
sample of 10 de-identified patient charts at the end of
each fidelity measurement month for patients seen dur-
ing that month. The clinic staff will generate a list of the
medical record numbers of all enrolled patients seen
during the last month and report the total number (N)
to the research team. The research team will use a sim-
ple computer-based randomization scheme to create an
equal length list consisting of “select” and “don’t select”
statements. Clinic staff will then match these lists and
pull and de-identify those charts whose medical record
numbers match up with the “select” statements. The
data to be extracted by the research team are intended
to assess IM whole person care (e.g., a review of systems
beyond those typically assessed in conventional care in-
cluding domains such as spirituality, social support, fam-
ily and work stressors, etc.), the patient-practitioner
partnership agreement, the mix of conventional and CM
therapies used, and lifestyle recommendations over the
past month. Visit lengths are also recorded.
Practitioner experiences survey
Practitioner experiences working in the UAIHC will be
assessed using the 27-item “How is UAIHC doing?”
Practitioner Version questionnaire developed for the fi-
delity study. Dimensions of the questionnaire assess the
team care climate of the clinic, practitioners’ stress and
self-care practices, and practitioners’ feedback on how
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care. The Team Climate Inventory (TCI) [75], a single-
item on practitioner burnout [76], as well as additional
individual items to account for IM principles will be ad-
ministered. It is estimated that it will take 10–15 minutes
for staff to complete this questionnaire.
Qualitative/case study data
The patients who have been selected for and agreed to
case study interviews will participate in a 20–30 minute
semi-structured interview immediately after each of the
outcomes data collection points. The patient’s outcome
results over time will be available to the interviewer, and
the interview will focus on the patient’s experience of
care at UAIHC and what the patient believes has con-
tributed to any health changes seen in the course of
treatment. These interviews will be either done by phone
or in person, and will be audiotaped and transcribed.
Analysis
Five sets of inter-related analyses are planned for these
data. The first will be a descriptive study based on the
demographics and baseline values of the first patients
(e.g., first 200) who join the study. The purpose of this
study and report is to document the characteristics,
diagnoses, symptoms and expectations of those patients
who choose to enroll in this integrative primary care
clinic. Where possible, patient characteristics, diagnoses
and symptoms will be compared to those seen nation-
ally and statewide in primary care using data from the
National Ambulatory Medical Care Survey (NAMCS)
[77]. Basic descriptive statistics will be used. When
comparisons are possible, will utilize t tests for inde-
pendent samples for continuous data, and χ2 tests for
frequencies.
The second analysis will use the fidelity monitoring
data to describe clinic operations and to describe how
this IM primary care clinic developed over time. Since
these are measures of the intervention itself (the clinic),
by design the patient fidelity sample measurements over
time will not be taken on the same individuals. There-
fore, data will be analyzed using simple descriptive sta-
tistics. The results will also be examined for trends using
regression analysis with time (either continuous or as a
set of dummy variables) as the main explanatory vari-
able, and significant t tests for the time coefficient(s) as
an indication of significant change over time in clinic
operations. Components of the clinic model that change
significantly over time and/or that contribute to the out-
comes will be considered as covariates in the two out-
comes studies described below [24].
The third analysis will involve data from the case study
participants. The narrative data from the transcribed,
audiotaped semi-structured interviews will be contentanalyzed using dedicated qualitative data analysis/text
management software (Atlas-ti), and key concepts will
be categorized into salient themes and patterns. Those
results will be related to each participant’s reported and
recorded outcomes to look for insights into clinic im-
pacts and operations.
The fourth and fifth analyses will be the main outcome
studies. The fourth study will be a prospective cohort
study of the changes in outcomes from baseline to one
year for all patients in the outcomes sample. The pri-
mary outcome for this analysis will be health-related
quality of life measured in three ways (SF-6D [78], and
the physical and mental component summary scores, all
derived from the SF-12), with the other outcomes as sec-
ondary measures. The main comparison will be baseline
to 12-month outcomes and the univariate analyses will
use paired t tests for continuous data, and use the
McNemar test for frequencies [79]. The data will also be
examined for patterns of change over time in key out-
comes, and the determinants of those patterns, using
hierarchical linear modeling (HLM) techniques [80-82].
Fidelity measures with significant changes over time will
be used as covariates [24] in these models, as well as
other explanatory variables such as demographics, par-
ticipants’ membership level and baseline diagnoses. If
participant numbers for each of the five targeted condi-
tion allow, condition-specific outcomes will be examined
for each. These same analyses will be applied to other
secondary outcomes such as CVD event [70] and mor-
tality [71] risk.
The fifth analysis will focus on the subset of patients
for which health insurance claims data are available and
will utilize a matched comparison design. Prior to ana-
lysis all claims data for each individual (treatment and
comparison groups) will be aggregated (by summation)
into per health plan member per month (PMPM) totals
of paid amounts (the amount paid by the health plan to
the practitioner) for each of the following cost categor-
ies: total, inpatient, outpatient, emergency room, phys-
ician, and pharmaceutical claims. Similarly, the numbers
of outpatient visits, hospital stays and emergency depart-
ment visits will also be aggregated for each individual.
The primary outcome will be total cost. Two comparison
groups from de-identified claims data will be created—
one using simple matching (e.g., by age and gender) and
one using propensity scores [49]. After the comparison
groups have been selected, simple descriptive analyses will
show average PMPM costs and healthcare utilization (in-
cluding standard deviations and other measures of disper-
sion) pre- and post- enrollment (or an equivalent date for
the comparison groups) by gender, age, baseline diagnosis
and by treatment and comparison group. Because cost
data tends to be highly skewed, average PMPM costs and
healthcare utilization pre/post enrollment, and the change
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and each of the comparison groups will be reported as
mean differences with confidence intervals calculated
using bootstrap methods [83,84]. Because of the number
of data points for each patient (e.g., up to 12 PMPM
values pre-enrollment and 12 post-enrollment), HLM
[80-82] will be used to estimate the pattern of change in
healthcare utilization and costs over time, and to explore
the determinants of those patterns. Fidelity measures with
significant changes over time [24], demographics, par-
ticipants’ membership level and baseline diagnoses will
be included as covariates in these models. Finally, changes
in costs between groups will be compared to changes in
patients’ CVD risk.
Results for the last two analyses will be reported fol-
lowing the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) guidelines [85]. For
all outcomes, the estimated treatment effects will be re-
ported using their original outcome scale and including
confidence intervals.
Discussion
There has been much written about the need for new
models of medical care—ones that are more patient-
centered, that can empower patients to make positive
lifestyle changes, that can lower cost of healthcare, and
that offer a sustainable financial model. This study has
been designed to test whether an IM primary care prac-
tice model (UAIHC) can meet these challenges.
This study will face a number of limitations. For ex-
ample, some of the self-report measures of fidelity have
not been fully tested and validated. The data collection
burden on patients might limit enrollment or increase
dropout. Also, because this is a new clinic, member enroll-
ment and study adoption rates are unknown and could fall
short of predictions. This is especially true for the five tar-
geted conditions; low prevalence will prevent analyses by
condition. Obtaining a useable set of claims data is always
challenging. Better outcomes (larger effect sizes) may be
achieved were factors in the clinic subject to more control
(e.g., patient homogeneity, or treatment consistency rather
than patient-centered care), or if the clinic had already
had time to mature into its final form. Also, at such an
early phase of the clinic’s development and management,
the methodological rigor required to study this multi-
faceted system of care may not be able to yield all of the
desired information. Instead, this will be an evaluation of
a newly designed and formed IM primary care clinic
model in its natural state as it evolves. Some of the data
collected during fidelity monitoring will also be useful in
improving and optimizing clinic performance. The addition
of more qualitative data collection is desirable to more
closely examine patient experiences in the clinic and may
be possible as funds and time become available.This protocol is designed to meet the methodological
challenges involved in evaluating this complex interven-
tion (IM model of adult primary care) with as much rigor
as possible. It is anticipated that its results and the results
of anticipated continuous evaluation of the UAIHC will
contribute greatly to health services research in integrative
medicine.
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